Objectives: The development of novel agents and an ageing population has led to an increasing number of patients with follicular lymphoma (FL) living longer with their disease. Health-related quality of life (HRQOL) is a priority for patients and should guide clinical decisions. The Myeloma Patient Outcome Scale (MyPOS), originally developed for myeloma, was validated in a cross-sectional survey recruiting 124 FL patients.
because of the increase in survival, long-term effects of therapy accumulate, among them toxicity-related symptoms, persistent fatigue, depression and anxiety. [5] [6] [7] [8] [9] [10] [11] These long-term effects have been shown in a recent systematic review to impact all dimensions of health-related quality of life (HRQOL) even at more than 5 years post-diagnosis. 10 Despite these long-term effects, research on HRQOL in NHL and FL patients is lacking. Only four studies so far have specifically focused on FL patients, documenting the effect of different modes of treatment on return to work and emotional well-being. 8, [11] [12] [13] Two systematic reviews of HRQOL in NHL present overall results for this group of haematological cancer patients. 10, 14 Both conclude that the paucity of evidence is caused in part by a lack of disease-specific HRQOL measures. Indeed, prior to 2013 no HRQOL measure was validated for use in NHL. The Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) 15 is the only questionnaire available, however, its validation study does not identify the proportion of FL in the sample. A further NHL-specific module of the European Organisation for Research and the Treatment of Cancer (EORTC) is currently being developed. 16 Moreover, as HRQOL and other patient-reported outcome measures are increasingly used in the clinical care of oncology patients, [17] [18] [19] a different type of measure, suitable for routine clinical use, is needed.
Measures developed for clinical use differ from HRQOL measures developed for use in research by a special focus on content and face validity, acceptability and interpretability. 20 The Myeloma Patient Outcome Scale (MyPOS) is such a measure, designed using extensive patient interviews, it is brief and suitable for use in clinical practice for measuring myeloma-specific HRQOL. 21 Given the comparability of disease trajectories (ranging from relatively indolent forms of FL and myeloma-spectrum diseases to relapsed/ refractory stages) and treatment-related side effects, 11, 13, 22, 23 suitability of MyPOS for use in FL is plausible. The objectives of this study are to test the construct and structural validity, examine the content validity and acceptability, and evaluate the reliability of MyPOS in FL patients.
| METHODS

| Setting and population
Between June and August 2013, patients with FL and myeloma were recruited for a self-completion, cross-sectional survey from outpatient clinics and inpatient wards in 13 hospital trusts in England, including a mix of tertiary and district general hospitals (see Acknowledgements for list of collaborators). In this paper, we focus on validation results for the sample of FL patients. Full details about the methods are reported in the validation study with myeloma patients. 24 Patients were included if they were 18 years or older, had a con- 
| Procedure
Consecutive (all available) patients seen on wards or in outpatient clinics at participating sites were screened by clinical teams for eligibility and if eligible offered the opportunity to participate in the survey by research staff. Participants were given the choice to complete the questionnaire at the point of recruitment or at a later date and to return the survey by post. Demographic and clinical data were extracted from medical records by research nurses at recruitment.
| Study measures
Questionnaire booklets contained MyPOS alongside two further measures for validation purposes; FACT-LYM and EORTC-QLQ-C30.
The latter two measures were chosen for testing convergent and divergent construct validity. They represent the only lymphoma-specific HRQOL questionnaire and the EORTC's core cancer questionnaire, which has been validated in lymphoma. 25 The MyPOS is a 30-item questionnaire, a myeloma-specific version of the Palliative Care Outcome Scale (http://pos-pal.org/ 
| Statistical analysis
The recruitment target was 111 participants, for detecting differences in MyPOS symptom and function subscale scores according to performance status, in a one-way ANOVA with small effects (0.03) and 80%
power. Data was double-entered into an SPSS database. All analyses were completed in SPSS v 22.0, 31 and in AMOS v. 22.0.
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The following psychometric properties were tested:
1. Construct validity: structural validity (factor analysis). Confirmatory factor analysis (CFA) was used to test the retention of the three-factor model (symptom and function, emotional response, and healthcare support) previously established for MyPOS in patients with myeloma. 24 The question about sex (item 6 on the MyPOS) was excluded from analyses due to a large proportion of missing data. Item parcelling, using the median score across four items related to gastro-intestinal symptoms (diarrhoea, constipation, nausea and vomiting) was also used to increase the participant to item ratio, in line with the recommend 5:1 ratio. 33, 34 Factorability of the matrix was tested using Bartlett's test of sphericity, seeking a large significant value indicating the MyPOS matrix was significantly different from a matrix with no correlations. 35 Given our small sample size, factorability was further confirmed in SPSS using the Kaiser-Meyer-Olkin Measure of Sampling Adequacy (MSA), applying Kaiser's criteria for 'good factor-analytic' of MSA≥0.80. 36 Initial CFA was carried out on the simplest uni-dimensional model, loading all items onto one factor. Different three-factor solutions were tested in contrast to this model. Three goodness-of-fit indices were used to compare models: Chi-square, Comparative Fit Index (CFI), and the Root mean square error of approximation (RMSEA). Because of the known limitation of the Chi-square χ 2 statistic with its sensitivity to sample size, the supplementary index; ratio of χ 2 to degrees of freedom (χ 2 /df) was used. A ratio of <2 is considered to reflect good model fit. 37 The CFI ranges from 0 to 1 and compares the model against the null model; a value >0.95 is considered representative of good fit. 38 For the RMSEA, 0.08 represents a reasonable fit. 39 Factor loadings of items on predicted factors were considered acceptable when above 0.30. 
| RESULTS
148 patients with FL were screened by clinical teams, seven were ineligible, 12 declined to participate and five withdrew from the study.
Sample characteristics are shown in Table 1 , and reasons for nonparticipation in Fig. S1 . (Table 3) .
| Structural validity: Confirmatory factor analysis (CFA)
'Tingling in hands and/or feet' was close to the lower threshold, with a loading of 0.314, suggesting a weaker correlation between this item and other items on the subscale. Eigenvalue estimates report 54.9% of the total variance explained by the three factors.
| Construct validity
The 
| Convergent and divergent validity
All, apart from one, of the hypotheses were confirmed within the predefined limits (for Pearson correlations see Table S2 ). MyPOS total scores 
| Content validity
Eighty-eight (80%) participants recorded some free text about their main problems or concerns at the beginning of the MyPOS questionnaire. In total, 148 main problems or concerns were reported (Tables S4a-S4c), with 112 (76%) of these being covered by a subsequent MyPOS item.
Of the 36 (24%) main problems and concerns not covered by a MyPOS item, only weight loss was reported multiple times, three separate participants citing it as a main problem or concern.
After grouping, the largest number of concerns (59 (40%)) were about participants worry for their disease or treatment, for example "always wondering when the lymphoma will become active again" and "worried about having chemo again", captured by MyPOS items 17, 18, 21, 22, and to some extent by items 26 and 27.
A total of 44 additional symptoms were recorded after the symptom list on the questionnaire (Table S5 ). The majority (35) were unique symptoms recorded only once. Four were about sweating, two of these specifically about night sweats, a further two about problems sleeping, and three referred to swelling in the legs, feet or ankles.
| Acceptability
Ten out of 27 MyPOS items had missing data; most (9) of these were missed by just one or two participants (see Table S1 ). By far the highest rate of missing data was observed for the question about sex; 13 items; the proportion of answers in the lowest category ranged from 23.4% to 91.9%. Ceiling effects were not present for any item.
| Reliability
The MyPOS total and subscale scores showed good internal consistency within the 0.70-0.95 desired range (Table 3) . More than 3 9 (7.3)
| DISCUSSION
One factor (no sex; n=118) Three factor (no sex; n=118) Three factor (no sex; gastro parcel; n=118) The chronic nature of MM, indolent NHL, and other conditions including, chronic lymphocytic leukaemia (CLL) and chronic myeloid leukaemia (CML), expose patients to the risk of long-term and accumulated effects of toxicity and adverse psychological effects associated with the pattern of disease relapse and remittance. 10, 23 Routine monitoring of HRQOL may be particularly beneficial in the care of these patients, helping to support palliation of symptoms and minimise the cumulative negative effects of treatment and disease on HRQOL. 14, 23 Of critical importance to greater integration of HRQOL in the clinical care of haematological cancer patients is the availability of valid and reliable tools, sensitive to specific disease-related outcomes, yet brief, and acceptable to patients and clinicians. 15 This is the first study to demonstrate the validity and reliability of a HRQOL measure for use in patients with FL as a distinct patient group. Although the MyPOS was originally developed for use in patients with myeloma, similarities between the two diseases and a lack of FL-specific tools, led us to validate the MyPOS in FL. Patient's 'main problems and concerns' were comprehensively covered.
Worry about disease or treatment was prominent, reaffirming the importance of comprehensively capturing these issues in the MyPOS. 
| Methodological limitations
This study is limited by its cross-sectional design. Validity and reliability, including longitudinal and inter-rater reliability have been established for the generic Palliative Care Outcome Scale from which the MyPOS is derived, 47 and work is currently underway to evaluate the test-retest reliability and responsiveness of MyPOS in detecting clinically important differences in myeloma patients over time. 48 This longitudinal analysis will strengthen our understanding of how to most effectively use MyPOS to improve patient care. Nevertheless, further disease-specific longitudinal validation of MyPOS in FL patients is needed to support the clinical use of this tool in measuring patient outcomes.
We did not seek access to records to compare our sample to the demographic and clinical characteristics of the wider group of patients registered at participating sites. Consecutive recruitment was used to maximise representativeness, and age and gender distributions reflected those in the wider FL population in the UK. 2 However, performance status and length of illness in our sample suggest that the very sickest patients, perhaps because they were non-ambulatory and confined to their homes, were excluded from our sampling frame. This The MyPOS has previously been demonstrated to be brief, with myeloma patients taking on average (mean) 7 minutes 19 seconds to complete the measure. Information on time taken to complete the MyPOS was recorded by research nurses for only 6 FL patients in this sample and is therefore not reported, this is an omission and should be prioritised in future studies.
Finally, we acknowledge that the confirmatory factor analysis was limited by a small participant to item ratio. Of main concern is that the structural validity of the item concerning worry about sex life has not been established, and the overall fit of the model fell short of predefined thresholds for 'good fit', therefore further factor analysis with a larger sample is required.
T A B L E 3 Confirmatory factor analysis (Model 3): standardised estimates for item factor loadings and communalities (n=118) 
